創美藥業(02289.HK):選舉嚴京斌出任董事會主席
格隆匯6月1日丨創美藥業(02289.HK)發佈公吿,姚創龍為了公司經營管理需要、強化分工職責、完善公司治理結構及滿足聯交所證券上市規則附錄十四所載企業管治守則守則條文第C.2.1條的規定的原因,不再擔任董事會主席,自2023年5月31日起生效。姚先生仍然擔任公司的執行董事及行政總裁。董事會已選舉非執行董事嚴京斌自2023年5月31日起接替姚先生出任董事會主席,並選舉姚先生出任董事會副主席。
張玲由於需投入更多精力處理其他個人事務,不再擔任公司監事會主席,自2023年5月31日起生效。張女士仍然擔任監事。監事會已選舉監事朱明洪接替張女士出任監事會主席,自2023年5月31日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.